On July 1, 2026 AB Science S.A. (the "Company" or "AB Science", Euronext – FR0010557264 – AB) reported the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors (the "Private Placement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the "AMF").

Use of proceeds

The Company intends to use the net proceeds of the Private Placement to finance research and development programs of the Company, the priority being the AB8939 program in acute myeloid leukemia and the masitinib in amyotrophic lateral sclerosis.

This transaction strengthens the Company’s cash position and enables it to cover its financing needs beyond the next 12 months.

Terms and conditions of the Private Placement

The Private Placement, for a total amount of EUR 2.3 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 3,475,758 new ordinary shares of the Company (the "New Shares"), each with one share warrant attached (a "BSA" and, together with the New Share to which it is attached, an "ABSA"). One BSA entitle their holder to subscribe to one new ordinary share of the Company at a price of EUR 0.93 per ordinary share. The issuance of the ABSA was conducted through a share capital increase with cancellation of shareholders’ preferential subscription rights for the benefit of investors within the category of persons defined by the 15th resolution of the Combined General Meeting of the Company’s shareholders of June 30, 2026 (the "General Meeting"), in accordance with article L. 225-138 of the French commercial code (the "Private Placement").

The issue of the ABSAs, representing approximately 4.54% of the Company’s share capital, on a non-diluted basis, before completion of the Private Placement, and 4.34% of the Company’s share capital, on a non-diluted basis, after completion of the Private Placement, was decided on June 30, 2026 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated June 30, 2026, pursuant to the delegation of competence granted to it under the 15th resolution of the General Meeting.

The issue price of one ABSA is EUR 0.66 (including share issue premium), representing a facial discount of 24.23% (i.e. EUR 0.2110) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ("Euronext Paris") over the three trading days preceding the setting of such issue price, i.e. June 26, 29 and 30, 2026, i.e. EUR 0.8710 (the "3-day VWAP").

The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the issue price of the new ordinary share issued upon exercise of one BSA) represents a total 24.56% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 15th resolution.

Terms and conditions of the BSA

One BSA is attached to each New Share.

One BSA entitle their holder to subscribe to one new ordinary share of the Company at a price of EUR 0.93 per ordinary share.

The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 3,475,758 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 3.2 million.

The theoretical value of each BSA, assuming a volatility of 32.088%1 and based on closing price as of June 30, 2026, is equal to EUR 0.2758 using Black & Scholes model.

The BSAs will be immediately detached (détachés) from the New Shares upon issuance and will not be listed.

Impact of the Private Placement on the Company’s shareholding

Following the issuance of the ABSAs, the Company’s total share capital will be EUR 800,296.65 (and EUR 835,054.23 in the event of exercise of all BSAs). It will be comprised of 73,251,991 ordinary shares (and of 76,727,749 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares.

To the Company’s knowledge, immediately prior to completion of the Private Placement and after completion of the Private Placement, the breakdown of the Company’s share capital is as follows:

Before the capital increase After the capital increase (before exercising the BSA) After the capital increase and exercise of the BSA
Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2)
A. Moussy 6 782 434 8,86% 15,41% 6 782 434 8,47% 14,90% 6 782 434 8,12% 14,42%
AMY SAS (3) 12 273 000 16,03% 12,12% 12 273 000 15,34% 11,72% 12 273 000 14,70% 11,34%
Subtotal concert A. Moussy 19 055 434 24,89% 27,54% 19 055 434 23,81% 26,62% 19 055 434 22,82% 25,77%
Other investors members of the concert 2 432 777 3,18% 5,27% 2 432 777 3,04% 5,09% 2 432 777 2,91% 4,93%
Actions in the pact 1 128 497 1,47% 3,98% 1 128 497 1,41% 3,85% 1 128 497 1,35% 3,72%
Actions outside the pact 1 304 280 1,70% 1,29% 1 304 280 1,63% 1,25% 1 304 280 1,56% 1,21%
Total concert 21 488 211 28,07% 32,80% 21 488 211 26,85% 31,71% 21 488 211 25,73% 30,69%
Other investors above 5% 6 888 610 9,00% 7,96% 6 888 610 8,61% 7,69% 6 888 610 8,25% 7,45%
Other investors 48 177 086 62,93% 59,24% 51 652 844 64,54% 60,59% 55 128 602 66,02% 61,86%
Total 76 553 907 100,00% 100,00% 80 029 665 100,00% 100,00% 83 505 423 100,00% 100,00%
(1) All classes of shares are affected. The number of ordinary shares amounts to 69,776,233 before the Private Placement, 73,251,991 after the Private Placement (but before exercise of the BSAs), and 76,727,749 after the Private Placement and exercise of the BSAs.
(2) The diluted basis takes into account the exercise of all instruments giving access to the capital, the definitive allocation of all free shares and the conversion of all preferred shares into ordinary shares (aiming for the highest theoretical dilution).
(3) AMY SAS is a company controlled by A. Moussy.

On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company’s share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.9566% on a non-diluted basis and 0.7309% on a diluted basis.

Admission to trading of the New Shares

The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on July 6, 2026.

The New Shares will be subject to the provisions of the Company’s by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company’s existing shares under the same ISIN code FR0010557264 – AB.

The BSAs will not be admitted to trading on any market.

The new ordinary shares issued upon exercise of the BSAs will be, when issued, subject to the provisions of the Company’s by-laws and will be assimilated to existing shares. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company’s existing shares under the same ISIN code FR0010557264 – AB.

Lock-up commitments

The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions.

The directors and officers of the Company have signed a lock-up commitment (to the benefit of the investors) pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions.

Financial Intermediaries

Maxim Group LLC acted as the sole placement agent in connection with the Private Placement.

Indicative timetable

June 30, 2026 Decisions of the Board of Directors deciding the principle of the Private Placement.
June 30, 2026 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement).
July 1st, 2026 Publication of this press release.

July 3, 2026 Settlement-delivery of the ABSAs – Detachment of the BSA

July 6, 2026 Start of trading of the New Shares on Euronext Paris.
Risk factors

AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company’s website (www.ab-science.com).

In addition, the main risks specific to securities are as follows:

The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions.

The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company’s shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price.

About masitinib

Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases.

About AB8939

AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications.

(Press release, AB Science, JUL 1, 2026, View Source [SID1234669031])

On July 1, 2026 Imugene Limited (ASX: IMU), a clinical-stage immunooncology company, reported additional patient data from the concurrent BTK inhibitor (BTKi) cohort of its ongoing Phase 1b basket study of azer-cel (azercabtagene zapreleucel).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Mantle Cell Lymphoma (MCL) patient, the first MCL patient treated in the azer-cel Phase 1b study, had previously failed BTKi therapy and achieved a complete response at the Day 28 assessment.

MCL is an aggressive B-cell non-Hodgkin lymphoma that typically presents at an advanced stage and remains incurable with standard therapies. BTK inhibitors have become an established treatment across relapsed or refractory MCL, but a significant proportion of patients develop resistance or intolerance over time, leaving them with limited remaining options.

All patients enrolled in the concurrent BTKi cohort have relapsed on or are refractory to BTKi therapy, a standard treatment across multiple B-cell malignancies. Despite the established efficacy of BTK inhibitors, a significant proportion of patients develop resistance over time and are left with limited remaining options. This cohort evaluates whether concurrent dosing of azer-cel with a BTKi may restore or enhance therapeutic activity in this setting. The global BTKi market reached approximately US$12.0 billion in 2025.

Leslie Chong, Managing Director and CEO of Imugene, said, "Achieving a second complete response in the concurrent BTKi cohort, including in the first Mantle Cell Lymphoma patient treated in the study, further reinforces our belief in azer-cel’s potential for patients who have progressed on BTKi therapy. Given the broad use of BTK inhibitors across B-cell malignancies and the limited treatment options available following progression, we believe this concurrent dosing approach represents a highly promising clinical and commercial opportunity for azer-cel."

To date, four patients have been dosed in the azer-cel Phase 1b concurrent BTKi cohort, two of which are evaluable, both achieving a complete response. Further updates will be provided as additional data becomes available, and the dataset matures.

Azer-cel is an off-the-shelf, allogeneic CAR T cell therapy which targets CD19 to treat blood cancers. Azer-cel is derived from healthy donor T cells and ready for administration within days, without the three-to-six-week manufacturing lead time required for autologous CAR T products.

About the Phase 1b azer-cel trial

The azer-cel allogeneic CAR T trial is an ongoing, open-label, multi-centre Phase 1b clinical trial in the U.S. and Australia, for CAR T relapsed patients and CAR T naïve patients diagnosed with a broad range of Non-Hodgkins lymphomas including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), and mantle cell lymphoma (MCL). The trial has most recently expanded into a concurrent BTKi cohort, for patients with a range of B-cell malignancies who have previously failed BTKi therapy. Treatment with azer-cel, lymphodepletion and IL-2 has produced meaningful clinical responses across multiple indications, including multiple complete responses in the concurrent BTKi cohort. Additionally, the safety profile is manageable and generally well tolerated.

(Press release, Imugene, JUL 1, 2026, View Source [SID1234669019])

On June 30, 2026 METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, reported it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Management, granting Boulevard worldwide development, manufacturing, and commercialization rights for MTS-128, a proprietary trispecific T-cell engager (TCE) program developed by METiS TechBio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

METiS TechBio will receive a $20 million upfront payment and is eligible to receive up to $1.6 billion in development, regulatory, and commercial milestone payments, in addition to tiered royalties on product sales.

METiS TechBio’s proprietary NanoForge platform has achieved deep integration across AI-based protein design, drug delivery system engineering, and therapeutic innovation, reflecting validation from top-tier global capital and industry partners. This transaction marks a shift in AI-enabled drug delivery platforms from early technological validation toward global commercialization value realization.

MTS-128 is a next-generation trispecific T-cell engager developed by METiS TechBio through its NanoForge platform. Unlike traditional antibody discovery approaches, MTS-128 is designed and optimized end-to-end through NanoForge-enabled AI-driven molecular engineering, representing a key example of AI-enabled therapeutic innovation at METiS TechBio.

Compared with conventional bispecific T-cell engagers, trispecific TCEs can simultaneously engage multiple biological mechanisms, with the potential to enhance target cell killing efficiency, increase therapeutic window and reduce off-target toxicity. The development of MTS-128 reflects METiS TechBio’s integrated capabilities in artificial intelligence and protein engineering, while also demonstrating NanoForge’s ability to continuously generate novel therapeutic assets.

METiS TechBio’s proprietary AI-enabled nanodelivery platform, NanoForge, is built on an integrated "dry lab + wet lab + agent-based intelligence" innovation framework, powering four core solution engines: AiLNP (AI-driven lipid nanoparticle design), AiRNA (AI mRNA sequence design), AiProtein (AI protein and antibody design), and AiTEM (AI small molecule formulation design).

NanoForge enables an end-to-end innovation chain spanning AI-based protein generation, in vivo delivery technologies, and next-generation immunotherapy development. In particular, the AiProtein platform supports rapid discovery and optimization of novel therapeutic proteins, including T-cell engagers, in vivo protein therapeutics, and other advanced immunomodulatory modalities.

"This transaction represents an exciting development in the strategic alliance between METiS and Deerfield at a pivotal moment for AI-driven drug delivery innovation in China," said Chris Lai, Chairman and Chief Executive Officer of METiS TechBio. "The MTS-128 program demonstrates NanoForge’s ability to enable next-generation drug discovery and development. This is only the beginning. Leveraging NanoForge as our core engine, we will continue to generate globally competitive therapeutic assets. As AI converges with drug delivery technologies, we aim to advance transformative therapies from concept to global development, bringing more accessible innovative treatments to patients worldwide."

Unlocking a healthier world through AI-driven nanotechnology. METiS Technologies (7666.HK) is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms. On May 13, 2026, METiS successfully listed on HK exchange as the first listed AI-powered drug delivery company.

Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed NanoForge, the world’s first AI-drive nano-delivery platform and four proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; AiProtein – AI platform for protein and antibody design and AiTEM – AI platform for small molecule formulation design.

(Press release, METiS TechBio, JUN 30, 2026, View Source [SID1234669030])

On June 30, 2026 Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, reported that the Research Council of Norway has approved a grant of NOK 16 million to Zelluna under the Innovation Project for the Industrial Sector (IPN) scheme.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NOK 16 million grant awarded by the Research Council of Norway
Funding will support Zelluna’s ongoing Phase 1 clinical study, ZIMA-101
The IPN scheme supports research-driven innovation projects in Norwegian industry and is administered by the Research Council of Norway
Award subject to final contract negotiations with the Research Council of Norway
"We are delighted to receive this support from the Research Council of Norway. The award provides meaningful funding for our Phase 1 clinical programme and represents strong external recognition of the innovation underpinning our TCR-NK platform and its potential to address significant unmet needs for patients with solid cancers," said Namir Hassan, CEO of Zelluna.

(Press release, Zelluna Immunotherapy, JUN 30, 2026, View Source [SID1234669029])

On June 30, 2026 Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover and develop precision medicines, reported the closing of an $85 million Series C financing led by existing investors. In connection with the financing, the company also announced the appointment of Anna Protopapas as Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing was led by Third Rock Ventures and Nextech Invest and included participation from Pfizer Ventures, Boxer Capital, GordonMD Global Investments LP, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital and Eventide Asset Management. Proceeds from the financing will be used to advance the Company’s prioritized programs, as well as for working capital and general corporate purposes.

Pipeline Prioritization

In connection with the financing, the Company has completed a strategic review of its pipeline and will concentrate resources on FX-111, a first-in-class, highly differentiated, potent and selective degrader targeting ARON, the transcriptionally active, hormone-bound androgen receptor for prostate cancer. By targeting ARON, FX-111 has the potential to overcome the key resistance mechanisms that limit conventional therapies directed at AROFF, particularly in high-risk AR-driven disease, with broad applicability across all stages of AR-driven disease. The Company received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and expects to initiate clinical development in the third quarter of 2026. FlareTx is also advancing an ARON Regulated Induced Proximity Targeting Chimeras (RIPTAC) program through preclinical development. This program complements FX-111 and further expands the Company’s ability to address prostate cancer across the full disease continuum.

"At Nextech, we focus capital where we see the strongest scientific and clinical conviction," said Kanishka Pothula, Managing Partner at Nextech Invest. "We believe FlareTx’s ARON-targeting approach is highly differentiated and has the potential to address important limitations of current prostate cancer therapies. This financing reflects our continued conviction in the team, the platform, and the potential of FX-111 to become an important therapy for patients with AR-driven prostate cancer."

"Our continued support of FlareTx into this next phase of growth is a testament to the differentiated transcription factor platform that has advanced novel programs into the clinic with potentially transformational impact to patients," said Abbie Celniker PhD, FlareTx founder and Partner at Third Rock Ventures. "We are also very pleased to welcome Anna Protopapas as incoming CEO. Her proven track record of leadership in oncology, spanning global development through commercialization, makes her exceptionally well suited to lead the Company."

FX-909, a first-in-class, orally available PPARG inhibitor targeting the luminal lineage biology underlying urothelial cancer, is currently being evaluated in a Phase 1B dose expansion study. The Company intends to advance this program through an external partnership to fully realize its potential, including opportunities to explore combination regimens and earlier lines of therapy where luminal lineage biology plays a defining role.

"This is an exciting time for Flare Therapeutics and for patients with prostate cancer who desperately need new options. FX-111 offers a new approach to targeting the androgen receptor pathway that has the potential to transform prostate cancer treatment across all stages of disease, while avoiding mechanisms of resistance, representing a genuinely differentiated opportunity," said Anna Protopapas, incoming Chief Executive Officer. "I am thrilled to lead a team that has proven it can advance a platform focused on drugging transcription factors and look forward to demonstrating that potential as we initiate our Phase 1A clinical study for FX-111 in the coming weeks."

CEO Appointment

Anna Protopapas joined the board of Flare Therapeutics in February 2025 and became Chair in September 2025. Most recently, Ms. Protopapas served as President and Chief Executive Officer of Mersana Therapeutics from 2015 until September 2023, where she led advancement of the company’s ADC platforms and pipeline, transitioning the company to a publicly traded entity and raised significant capital through partnerships and equity financing. Prior to Mersana, Ms. Protopapas was President of Millennium, a wholly owned subsidiary of Takeda, where she led Takeda’s oncology business. Ms. Protopapas also served as Executive Vice President of Global Business Development at Takeda, where she led acquisitions and partnerships that helped catalyze Takeda’s growth and globalization. Earlier, Ms. Protopapas was an executive officer at Millennium and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader and the subsequent acquisition of the company by Takeda. Ms. Protopapas has served as the Chair of the Board at Nuvalent since early 2022 (recently announced to be acquired by GSK for $10.6B) and previously served on the boards of ARIAD Pharmaceuticals (acquired by Takeda), Bioverativ (acquired by Sanofi) and Dicerna (acquired by Novo Nordisk) and Mersana Therapeutics (acquired by Day One). She received her B.S. in Science and Engineering from Princeton University, M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology and M.B.A. from Stanford Graduate School of Business.

(Press release, Flare Therapeutics, JUN 30, 2026, View Source [SID1234669028])